Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MED and 80,000+ other tickers.
See exactly how MED's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MED and 80,000+ other tickers.
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The…
MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through rigorous research and credible, evidence-based education. The institute brings Medifast's clinical research, scientific expertise, and educational resources under a single body, solidifying the company's position in the metabolic health space. It follows the July launch of Trilivy™, which replaced OPTAVIA® as the company's co.
MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.